United Kingdom· GB-APID-12207711000001108
Atriance 250mg/50ml solution for infusion vials
A nelarabine product containing nelarabine, registered in United Kingdom by Sandoz Ltd. The same ATC class is registered in 13 of our 19 countries.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
Where it is registered
Nelarabine is registered in 13 of 19 countries.
Countries holding a registration under ATC L01BB07 (nelarabine), each read from that country’s own register.
- This record: United Kingdom, from NHS dm+d (United Kingdom)
- 8 of them publish a price we can compare per daily dose
Nelarabine · ATC L01BB07
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Nelarabine
- Manufacturer
- Sandoz Ltd
- Country
- United Kingdom (GB)
- ATC code
- L01BB07
- ATC class
- Nelarabine
- Defined daily dose
- 0.39 g, P
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 3
- gtin5000123112524
- gtin07612797547946
- gtin07613421165338
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
201 interactions on record for nelarabine.
Graded by severity as the source publishes them — 35 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Nelarabine · interactions on record
201 records
- 35 severe
- 166 moderate
Most severe, free to view
- CladribineL01BB04severe
- Talimogene laherparepvecL01XL02severe
- Talimogen laherparepvecL01XX51severe
- LeflunomidL04AA13severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Nelarabine in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesArranonNovartis Pharmaceuticals Corporation
- FinlandAtrianceOrifarm Oy
- CzechiaATRIANCESandoz Pharmaceuticals d.d., Ljubljana
- SpainATRIANCE 5 MG/ML SOLUCION PARA PERFUSIONSandoz Pharmaceuticals D.D.
- BelgiumAtriance 5 mg/mlSandoz Pharmaceuticals
- IrelandATRIANCE 5mg/ml Solution for InfusionSandoz Pharmaceuticals d.d.
- IcelandAtrianceSandoz Pharmaceuticals d.d.
- NetherlandsAtriance 5 mg/ml oplossing voor infusieSandoz Pharmaceuticals d.d.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Atriance
- Liechtenstein · Atriance
- Norway · Atriance
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d3f425bf-b393-45a0-bd2f-9d7a6b21ee4d GET /v1/drugs/d3f425bf-b393-45a0-bd2f-9d7a6b21ee4d?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "12207711000001108",
"desc": "Atriance 250mg/50ml solution for infusion vials (Sandoz Ltd)",
"form": "Solution for infusion",
"vpid": "12212411000001103",
"source": "dmd",
"vtm_id": "776883005",
"strength": "5 mg",
"substance": "Nelarabine",
"ingredient": "Nelarabine",
"supplier_code": "2074301000001102"
}See everything about nelarabine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.